Cargando…

Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan

OBJECTIVE: To evaluate drug-drug interactions (DDIs) between gefitinib or erlotinib with fluoxetine, and/or losartan. METHODS: Human pooled microsomes, supersomes, and cryopreserved human hepatocytes were used to monitor DDIs in vitro. RED (Rapid Equilibrium Dialysis) protein binding was employed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luong, Thu-Lan T., McAnulty, Michael J., Evers, David L., Reinhardt, Brian J., Weina, Peter J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320603/ https://www.ncbi.nlm.nih.gov/pubmed/34345864 http://dx.doi.org/10.1016/j.crtox.2021.05.006

Ejemplares similares

Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine
por: Luong, Thu-Lan T., et al.
Publicado: (2022)

Role of cytochrome P450 in drug interactions
por: Bibi, Zakia
Publicado: (2008)

Effects of Tenapanor on Cytochrome P450‐Mediated Drug‐Drug Interactions
por: Johansson, Susanne, et al.
Publicado: (2017)

DDI-MuG: Multi-aspect graphs for drug-drug interaction extraction
por: Yang, Jie, et al.
Publicado: (2023)

Metabolic Glycoengineering Sensitizes Drug-Resistant Pancreatic Cancer Cells to Tyrosine Kinase Inhibitors Erlotinib and Gefitinib
por: Mathew, Mohit P., et al.
Publicado: (2015)

Retraction: Role of cytochrome P450 in drug interactions
por: Bibi, Zakia
Publicado: (2014)

Cytochrome P450 Enzymes and Drug Metabolism in Humans
por: Zhao, Mingzhe, et al.
Publicado: (2021)

DeSIDE-DDI: interpretable prediction of drug-drug interactions using drug-induced gene expressions
por: Kim, Eunyoung, et al.
Publicado: (2022)

Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo
por: Wang, Yiran, et al.
Publicado: (2020)

In Silico Prediction of Drug–Drug Interactions Mediated by Cytochrome P450 Isoforms
por: Dmitriev, Alexander V., et al.
Publicado: (2021)

Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children
por: Aka, Ida, et al.
Publicado: (2017)

Comparative Cytochrome P450 In Vitro Inhibition by Atypical Antipsychotic Drugs
por: Gervasini, Guillermo, et al.
Publicado: (2013)

AttentionDDI: Siamese attention-based deep learning method for drug–drug interaction predictions
por: Schwarz, Kyriakos, et al.
Publicado: (2021)

Drug-drug interaction of acetaminophen and roxithromycin with the cocktail of cytochrome P450 and hepatotoxicity in rats
por: Liu, Xiang, et al.
Publicado: (2020)

Use of Drugs that Act on the Cytochrome P450 System in the Elderly
por: Cabrera, Marcos A S, et al.
Publicado: (2009)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

Drug-drug interactions: it is not only CYP450's which matter
por: Back, David J
Publicado: (2010)

Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein
por: Zahir, Hamim, et al.
Publicado: (2020)

DDI-CPI, a server that predicts drug–drug interactions through implementing the chemical–protein interactome
por: Luo, Heng, et al.
Publicado: (2014)

SignalDetDDI: An SAS macro for detecting adverse drug-drug interactions in spontaneous reporting systems
por: Gosho, Masahiko, et al.
Publicado: (2018)

DDI-PULearn: a positive-unlabeled learning method for large-scale prediction of drug-drug interactions
por: Zheng, Yi, et al.
Publicado: (2019)

African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development
por: Rajman, Iris, et al.
Publicado: (2017)

An update on the role of intestinal cytochrome P450 enzymes in drug disposition
por: Xie, Fang, et al.
Publicado: (2016)

Effect of health foods on cytochrome P450-mediated drug metabolism
por: Sasaki, Takamitsu, et al.
Publicado: (2017)

A history of the roles of cytochrome P450 enzymes in the toxicity of drugs
por: Guengerich, F. Peter
Publicado: (2020)

Inflammatory signaling on cytochrome P450-mediated drug metabolism in hepatocytes
por: Wang, Xiaokang, et al.
Publicado: (2022)

Correction: Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2012)

Does DDI-Predictor Help Pharmacists to Detect Drug-Drug Interactions and Resolve Medication Issues More Effectively?
por: Moreau, Fanny, et al.
Publicado: (2021)

CNN-DDI: a learning-based method for predicting drug–drug interactions using convolution neural networks
por: Zhang, Chengcheng, et al.
Publicado: (2022)

Metabolism of 4-Aminopiperidine Drugs by Cytochrome P450s: Molecular and Quantum Mechanical Insights into Drug Design
por: Sun, Hao, et al.
Publicado: (2011)

Potential Cytochrome P450 Drug-Drug Interaction Among Adult and Adolescent Patients Undergoing Tonsillectomy
por: Nimmagadda, Sai, et al.
Publicado: (2020)

In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug–drug interactions
por: Wójcikowski, Jacek, et al.
Publicado: (2020)

Prediction of cytochrome P450-mediated drug clearance in humans based on the measured activities of selected CYPs
por: Gao, Jie, et al.
Publicado: (2017)

Drug-Induced Liver Injury Due To Losartan
por: Diogo, Joana, et al.
Publicado: (2021)

Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.
por: Meyer, U. A.
Publicado: (1996)

Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule
por: Mishra, Nitish K, et al.
Publicado: (2010)

Role of cytochrome P450 genotype in the steps toward personalized drug therapy
por: Cavallari, Larisa H, et al.
Publicado: (2011)

Cytochrome P450 enzyme mediated herbal drug interactions (Part 1)
por: Wanwimolruk, Sompon, et al.
Publicado: (2014)

Cytochrome P450 enzyme mediated herbal drug interactions (Part 2)
por: Wanwimolruk, Sompon, et al.
Publicado: (2014)

Structure-Based Drug Design for Cytochrome P450 Family 1 Inhibitors
por: Dutkiewicz, Zbigniew, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tjj422bhgupm8tl0jl2jb0ugqt